October 24th 2024
Nina Vadiei, PharmD, BCPP, a clinical associate professor at UT Austin and a clinical pharmacy specialist in psychiatry at San Antonio State Hospital, discusses her career as a psychiatric pharmacist.
Medications help adults quit smoking
September 11th 2012Adults are more likely to successfully quit smoking if they take bupropion, varenicline (Chantix), or a nicotine patch, than those who attempt to quit without medication, according to the results of an ongoing prospective cohort survey published by the journal Addiction.
Azilsartan medoxomil-chlorthalidone fixed combination superior at reducing blood pressure
September 11th 2012A fixed-dose combination of azilsartan medoxomil plus chlorthalidone (Edarbyclor, Takeda) was statistically superior to azilsartan medoxomil coadministered with hydrochlorothiazide at reducing and maintaining systolic blood pressure, according to the results of a phase 3 study published online August 31 in The American Journal of Medicine.
Acetaminophen dosing guidelines needed for overweight children, study shows
September 5th 2012There is considerable discrepancy among caregivers and pharmacists regarding the appropriate dosage of acetaminophen for overweight and obese children, according to a recent study published online August 20 in the European Journal of Hospitality.
Early administration of aspirin plus alteplase does not improve outcome in stroke patients
September 5th 2012Early administration of intravenous aspirin, in addition to alteplase, does not improve functional outcome at 3 months for patients with acute ischemic stroke, but increases the risk of symptomatic intracranial hemorrhage, according to a study published online August 25 in The Lancet.
Aspirin may benefit prostate cancer patients
September 5th 2012Anticoagulant therapy, particularly the use of aspirin, may reduce the risk of prostate cancer-specific mortality in men treated with radical prostatectomy or radiotherapy for prostate cancer, according to a study published online August 27 in the Journal of Clinical Oncology.
New anticancer agents may lead to greater toxicity, discontinuation rates than standard therapy
September 4th 2012New anticancer agents that offer improved efficacy compared with standard therapy also increase morbidity and treatment-related mortality, according to a meta-analysis published August 20 in the Journal of Clinical Oncology.
FDA approves new treatment for a type of late-stage prostate cancer
August 31st 2012FDA approved enzalutamide (Xtandi, Astellas Pharma U.S. Inc. and Medivation) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
Use of ALBC implants may lead to kidney injury
August 23rd 2012Aminoglycoside-loaded bone cement implants, frequently used in orthopedic surgery, may result in systemic effects that raise aminoglycoside serum concentrations and lead to acute kidney injury, according to a study published July 3 in The Annals of Pharmacotherapy.